PDS Biotech Q3 net loss $10.8M; highlights 74% 2-year OS in VERSATILE-002 trial

PDS Biotechnology Corp

2023-Q3 EPS reported -$1.04

Net loss of $10.8M ($0.35/share) vs $7.4M loss in Q3 2022; R&D expenses rose to $6.4M from $4.4M.
Cash $54.3M at Sept 30, expected to fund operations into Q3 2024; VERSATILE-003 Phase 3 initiation planned Q1 2024.
VERSATILE-002 interim: 24-month overall survival rate of 74% in ICI-naïve HPV+ head & neck cancer patients.
NCI triple combo: 75% of ICI-naïve HPV+ cancer patients alive at 36 months; median OS not reached.
PDS01ADC+docetaxel: PSA decreased in all 18 prostate cancer patients; 61% had ≥60% PSA decline.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PDS Biotechnology Corp reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 14, 2023, PDS Biotechnology Corporation (the “Company”) issued a press release announcing its financial results as of and for the three and nine months ended September 30, 2023 and provided an update on the business of the Company.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-23-053099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.